Payment overview · 2025
General Payments
$285.83
15 reported records · 11 companies
Healthcare provider profile · identity verified
Amy J Cofer, P.A.
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · GRIFFIN, GA · NPI 1831173939
Verified facts
What the public records show
CMS Open Payments records show Amy J Cofer, P.A. received $285.83 in general payments during 2025 across 15 reported records.
Novo Nordisk Inc accounted for 22.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Nurtec Odt, Ozempic, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $64.75 | 22.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $40.16 | 14.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.18 | 10.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $25.42 | 8.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.86 | 8.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.28 | 7.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.72 | 6.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.31 | 6.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.44 | 5.4% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$15.40 | 5.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.31 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $285.83 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $43.73 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $40.16 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $40.16 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.18 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.18 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $25.42 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.86 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.02 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.02 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.28 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 98 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 59 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 169 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 68 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
49 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
59 | 18 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
52 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
94 | 24 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
59 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
68 | 49 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
67 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
169 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
98 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 715 | 224 |
| Levothyroxine Sodium | Levothyroxine Sodium | 490 | 133 |
| Amlodipine Besylate | Amlodipine Besylate | 390 | 123 |
| Pantoprazole Sodium | Pantoprazole Sodium | 330 | 98 |
| Lisinopril | Lisinopril | 275 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 260 | 75 |
| Furosemide | Furosemide | 243 | 86 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 232 | 70 |
| Gabapentin | Gabapentin | 225 | 66 |
| Alprazolam | Alprazolam | 205 | 49 |
| Omeprazole | Omeprazole | 205 | 63 |
| Simvastatin | Simvastatin | 191 | 52 |
| Losartan Potassium | Losartan Potassium | 188 | 57 |
| Escitalopram Oxalate | Escitalopram Oxalate | 175 | 58 |
| Montelukast Sodium | Montelukast Sodium | 174 | 58 |
| Ozempic | Semaglutide | 169 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 159 | 52 |
| Zolpidem Tartrate | Zolpidem Tartrate | 158 | 34 |
| Tramadol Hcl | Tramadol Hcl | 143 | 38 |
| Metformin Hcl | Metformin Hcl | 141 | 43 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 130 | 39 |
| Potassium Chloride | Potassium Chloride | 123 | 46 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 122 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 121 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 120 | 47 |
| Prednisone | Prednisone | 116 | 66 |
| Clonazepam | Clonazepam | 115 | 22 |
| Trazodone Hcl | Trazodone Hcl | 114 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 111 | 34 |
| Sertraline Hcl | Sertraline Hcl | 110 | 32 |
| Ibandronate Sodium | Ibandronate Sodium | 108 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 106 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 104 | 33 |
| Trulicity | Dulaglutide | 103 | 18 |
| Mounjaro | Tirzepatide | 102 | 18 |
| Eliquis | Apixaban | 98 | 24 |
| Bupropion Xl | Bupropion Hcl | 94 | 31 |
| Farxiga | Dapagliflozin Propanediol | 94 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 91 | 24 |
| Pregabalin | Pregabalin | 89 | 32 |
| Temazepam | Temazepam | 88 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 86 | 20 |
| Glimepiride | Glimepiride | 85 | 27 |
| Allopurinol | Allopurinol | 82 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 20 |
| Carvedilol | Carvedilol | 78 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 71 | 18 |
| Estradiol | Estradiol | 70 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 69 | 26 |
| Lorazepam | Lorazepam | 68 | 25 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 68 | 49 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | 15 |
| Memantine Hcl | Memantine Hcl | 66 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 65 | 57 |
| Meloxicam | Meloxicam | 62 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 19 |
| Jardiance | Empagliflozin | 59 | 13 |
| Synthroid | Levothyroxine Sodium | 59 | 18 |
| Valsartan | Valsartan | 59 | 17 |
| Chlorthalidone | Chlorthalidone | 58 | 17 |
| Famotidine | Famotidine | 58 | 24 |
| Colesevelam Hcl | Colesevelam Hcl | 56 | 16 |
| Buspirone Hcl | Buspirone Hcl | 55 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 15 |
| Topiramate | Topiramate | 53 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 17 |
| Myrbetriq | Mirabegron | 52 | 16 |
| Atenolol | Atenolol | 49 | 13 |
| Linzess | Linaclotide | 49 | 18 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 49 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 49 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 14 |
| Metformin Hcl Er | Metformin Hcl | 45 | 18 |
| Nystatin | Nystatin | 44 | 18 |
| Glipizide Er | Glipizide | 43 | 12 |
| Sucralfate | Sucralfate | 42 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 27 |
| Propranolol Hcl | Propranolol Hcl | 41 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 39 | 16 |
| Donepezil Hcl | Donepezil Hcl | 38 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | 17 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 16 |
| Finasteride | Finasteride | 35 | suppressed |
| Primidone | Primidone | 35 | suppressed |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 24 |
| Januvia | Sitagliptin Phosphate | 32 | 12 |
| Repatha Sureclick | Evolocumab | 32 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | suppressed |
| Ibuprofen | Ibuprofen | 28 | 12 |
| Azelastine Hcl | Azelastine Hcl | 27 | suppressed |
| Lamotrigine | Lamotrigine | 27 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 27 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | 16 |
| Celecoxib | Celecoxib | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 17 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 12 |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 17 |
| Bumetanide | Bumetanide | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Nystop | Nystatin | 19 | 11 |
| Spironolactone | Spironolactone | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Invokana | Canagliflozin | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 16 | 15 |
| Ciclopirox | Ciclopirox | 16 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 13 | 13 |
| Baclofen | Baclofen | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $285.83 · 15 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, Dexcom G6 Transmitter, ELIQUIS, ETERNA, JARDIANCE, MINIMED 780G, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, SHINGRIX, UBRELVY, Veozah, Wegovy | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error